Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide|DRUG: Docetaxel, cyclophosphamide
Sponsor: Shanghai Jiao Tong University School of Medicine